Liposome-Delivered GHK-Cu Peptide Inhibits Nearly Half of Skin-Degrading Elastase Activity

What the researchers found

Key results for liposome-delivered GHK-Cu:

- Stable liposomes of approximately 100 nm were produced using both anionic (AL) and cationic (CL) hydrogenated lecithin

- Cationic liposomes at 25 mg/cm³ hydrated with 0.5 mg/cm³ GHK-Cu achieved the best encapsulation efficiency: 31.7 ± 0.9%

- Anionic liposomes achieved 20.0 ± 2.8% encapsulation

- Cationic liposomes had higher bilayer fluidity

- GHK-Cu inhibited elastase activity by 48.90 ± 2.50%

- GHK-Cu did not significantly affect tyrosinase activity

- The 49% elastase inhibition supports skin structural integrity by reducing elastin degradation

Why it matters

GHK-Cu is one of the most studied cosmetic peptides, with evidence for stimulating collagen production, wound healing, and anti-aging effects. However, its effectiveness depends on reaching the right skin layers. This study demonstrates that liposome encapsulation can deliver GHK-Cu while preserving its biological activity, and the strong elastase inhibition (49%) provides a specific mechanism for its anti-aging effects — protecting the elastin network that keeps skin firm and resilient.

How the study worked

Liposomes were prepared using the thin-film hydration method combined with freeze-thaw cycles and extrusion. Both anionic and cationic formulations were tested with varying lipid content, composition, and GHK-Cu concentrations. Physicochemical properties (size, stability, bilayer fluidity) and peptide encapsulation efficiency were characterized. In vitro enzyme inhibition assays measured tyrosinase and elastase activity.

What this study cannot tell us

This is entirely an in vitro formulation study — no skin penetration tests, cell culture viability assays, or clinical testing was performed. The 31.7% encapsulation efficiency means most of the GHK-Cu is not captured by the liposomes. The liposome stability over time during storage was not fully characterized. The elastase and tyrosinase assays are simplified models that may not fully represent skin biology. No comparison to free (unencapsulated) GHK-Cu was described in the abstract.

How to read the evidence

This is a formulation science study focused on liposome characterization and in vitro enzyme inhibition. While technically sound for its purpose, the evidence is at the formulation development stage — far from clinical proof of efficacy. The elastase inhibition data is promising but needs skin penetration and clinical validation.

When this study was published

Published in 2023, this study reflects current formulation science approaches for peptide delivery in cosmetic applications. GHK-Cu remains one of the most actively researched cosmetic peptides.

The bigger picture

Peptide delivery is one of the major challenges in both pharmaceutical and cosmetic applications. Liposomes offer a solution by protecting peptides from degradation while enhancing skin penetration. This study contributes to the growing field of peptide-loaded nanocarriers for skincare, demonstrating that carefully designed delivery systems can maintain peptide bioactivity. As consumer demand for science-backed cosmetic peptides grows, delivery technology will be a key differentiator.

Questions still open

• How does liposome-delivered GHK-Cu penetrate human skin compared to free peptide in ex vivo or clinical studies?
• Can encapsulation efficiency be improved beyond 31.7% with alternative liposome formulations or preparation methods?
• Does the elastase inhibition seen in vitro translate to visible anti-aging effects in clinical skin studies?

Common questions

Read the original research

Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application.

Pharmaceutics, 15(10)

Citation

Dymek, Michał; Olechowska, Karolina; Hąc-Wydro, Katarzyna; Sikora, Elżbieta. (2023). Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application.. Pharmaceutics, 15(10). https://doi.org/10.3390/pharmaceutics15102485